OA
RPRX icon

Oxbow Advisors’s Royalty Pharma RPRX Stock Holding History

Oxbow Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.15M Buy
86,516
+198
+0.2% +$8.67K 0.35% 76
2025
Q4 		$3.34M Buy
86,318
+1,577
+2% +$60.1K 0.29% 92
2025
Q3 		$2.99M Buy
+84,741
New +$3.07M 0.28% 87

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Oxbow Advisors's RPRX Position: Q1 2026 in Review

Oxbow Advisors increased its Royalty Pharma (RPRX) stake by 0.23% in Q1 2026, buying an estimated $8.67K and bringing the position to 86,516 shares worth $4.15M. The position accounts for 0.35% of the portfolio, ranked #76.

Oxbow Advisors first reported a position in RPRX in Q3 2025 and has held it in 3 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Oxbow Advisors held 86,516 shares of Royalty Pharma worth $4.15M as of Q1 2026.
  • Oxbow Advisors bought 198 Royalty Pharma shares in Q1 2026, an estimated $8.67K.
  • Royalty Pharma made up 0.35% of Oxbow Advisors's portfolio in Q1 2026, its #76 holding.
  • Oxbow Advisors first reported a position in Royalty Pharma in Q3 2025 and has held it in 3 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Oxbow Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.